Equities research analysts predict that Revance Therapeutics Inc (NASDAQ:RVNC) will post ($0.83) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Revance Therapeutics’ earnings. The lowest EPS estimate is ($0.88) and the highest is ($0.77). Revance Therapeutics posted earnings per share of ($0.97) in the same quarter last year, which would indicate a positive year-over-year growth rate of 14.4%. The business is expected to issue its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Revance Therapeutics will report full year earnings of ($3.54) per share for the current fiscal year, with EPS estimates ranging from ($3.80) to ($3.33). For the next financial year, analysts anticipate that the company will report earnings of ($3.53) per share, with EPS estimates ranging from ($4.45) to ($2.67). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.17). Revance Therapeutics had a negative net margin of 3,824.22% and a negative return on equity of 73.66%.
A number of research firms have weighed in on RVNC. ValuEngine raised Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. SunTrust Banks reduced their price objective on Revance Therapeutics to $29.00 and set a “buy” rating on the stock in a research note on Friday, March 1st. Mizuho reaffirmed a “buy” rating on shares of Revance Therapeutics in a research note on Wednesday, February 27th. Finally, Wells Fargo & Co started coverage on Revance Therapeutics in a research note on Friday, February 15th. They issued a “market perform” rating and a $17.83 price objective on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $33.26.
Shares of RVNC traded up $0.26 on Friday, hitting $13.49. The company’s stock had a trading volume of 311,386 shares, compared to its average volume of 318,629. Revance Therapeutics has a fifty-two week low of $12.87 and a fifty-two week high of $34.20. The firm has a market capitalization of $593.96 million, a PE ratio of -3.42 and a beta of 0.83.
In other news, CEO L Daniel Browne sold 11,613 shares of the company’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.51, for a total transaction of $180,117.63. Following the transaction, the chief executive officer now owns 165,687 shares of the company’s stock, valued at approximately $2,569,805.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 18,182 shares of company stock worth $295,218. Insiders own 5.20% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Rothschild & Co. Asset Management US Inc. boosted its stake in shares of Revance Therapeutics by 1.2% in the 4th quarter. Rothschild & Co. Asset Management US Inc. now owns 49,441 shares of the biopharmaceutical company’s stock worth $995,000 after buying an additional 590 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Revance Therapeutics by 8.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 11,492 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 900 shares during the last quarter. Legal & General Group Plc lifted its position in Revance Therapeutics by 21.7% during the fourth quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 1,150 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Revance Therapeutics by 97.2% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,352 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 1,159 shares in the last quarter. Finally, Teachers Advisors LLC lifted its position in Revance Therapeutics by 4.6% during the third quarter. Teachers Advisors LLC now owns 62,902 shares of the biopharmaceutical company’s stock valued at $1,563,000 after purchasing an additional 2,741 shares in the last quarter. Institutional investors own 79.90% of the company’s stock.
About Revance Therapeutics
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
Recommended Story: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.